A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma

Nucleic Acid Therapeutics

Volumn 27, Issue 1, 2017, Pages 23-35

  Clawson, Gary A ^a   Abraham, Thomas ^a   Pan, Weihua ^a   Tang, Xiaomeng ^b   Linton, Samuel S ^a   McGovern, Christopher O ^a   Loc, Welley S ^b   Smith, Jill P ^c   Butler, Peter J ^b   Kester, Mark ^d   Adair, James H ^b   Matters, Gail L ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

DNA aptamer; Pancreatic cancer; Targeted nanoparticles; Tumor imaging

Indexed keywords

AP 1153; APTAMER; CHOLECYSTOKININ B RECEPTOR; DNA; UNCLASSIFIED DRUG; NANOCONJUGATE;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG TARGETING; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; CV-1 CELL LINE; DRUG DELIVERY SYSTEM; DRUG SCREENING; FLUORESCENCE IMAGING; GENETICS; HUMAN; MALE; METABOLISM; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; THERANOSTIC NANOMEDICINE; THREE DIMENSIONAL IMAGING; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG DELIVERY SYSTEMS; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NANOCONJUGATES; OPTICAL IMAGING; PANCREATIC NEOPLASMS; RECEPTOR, CHOLECYSTOKININ B; THERANOSTIC NANOMEDICINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85011320231     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2016.0621     Document Type: Article

References (44)

1. Rahib L, BD Smith, R Aizenberg, AB Rosenzweig, J Fleshman and LM Matrisian. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, pancreas cancers in the United States. Cancer Res 74:2913-2921.
2. Klemm F and JA Joyce. (2015). Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 25:198-213.
3. Byrne JD, T Betancourt and L Brannon-Peppas. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615-1626.
4. Yu MK, J Park and S Jon. (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2:3-44.
5. Panyam J and V Labhasetwar. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissues. Adv Drug Deliv Rev 55:329-347.
6. Daniels TR, E Bernabeu, JA Rodriguez, S Patel, M Kozman, DA Chiappetta, E Holler, JY Ljubimova, G Helguera and ML Penichet. (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820:291-317.
7. Basile L, R Pignatello and C Passirani. (2012). Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv 9:255-268.
8. Wu X, J Chen, M Wu and JX Zhao. (2015). Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics 5:322-344.
9. Sun H and Y Zu. (2015). Aptamers and their applications in nanomedicine. Small 11:2352-2364.
10. Dhar S, FX Gu, R Langer, OC Farokhzad and SJ Lippard. (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356-17361.
11. Dhar S, N Kolishetti, SJ Lippard and OC Farokhzad. (2011). Targeted delivery of cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108:1850-1855.
12. Ray P, MA Cheek, ML Sharaf, N Li, AD Ellington, BA Sullenger, BR Shaw and RR White. (2012). Aptamermediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther 22:295-305.
13. Pei X, J Zhang and J Liu. (2014). Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol 2:341-348.
14. Sun H, X Zhu, PY Lu, RR Rosato, W Tan and Y Zu. (2014). Oligonucleotide aptamers: new tools for targeted cancer therapy. Nuclic Acids 3:e182.
15. Goetze JP and FC Nielsen. (2000). Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 88:2487-2494.
16. Nock BA, T Maina, M Behe, A Nikolopoulou, M Gotthardt, JS Schmitt, TM Behr and HR Macke. (2005). CCK-2/gastrin receptor-targeted tumor imaging with (99 m)Tclabeled minigastrin analogs. J Nucl Med 46:1727-1736.
17. Laverman P, L Joosten, A Eek, S Roosenburg, PK Peitl, T Maina, H Macke, L Aloj, E von Guggenberrg, , et al. (2011). Comparative biodistribution of 12(1)(1)(1)In-labeled gastrin/CCK2 receptor-targeting peptides. J Nucl Med Mol Imaging 38:1410-1416.
18. Kossatz S, M Behe, R Mansi, D Saur, P Czerney, WA Kaiser and I Hilger. (2013). Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. Biomaterials 34: 5172-5180.
19. Long J, G Luo, C Liu, X Cui, K Satoh, Z Xiao, B Zhang, J Xu, Q Ni, , et al. (2012). Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Int J Oncol 41:1662-1668.
20. Wayua C and PS Low. (2015). Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers. J Nucl Med 56:113-119.
21. Sturzu A, S Sheikh, U Klose, H Echner, H Kalbacher, M Deeg, T Nagele, M HOrger, C Schwentner, , et al. (2012). Potential of the gastric motility drug lorglumide in prostate cancer imaging. Eur J Pharm Sci 45:575-580.
22. Sanchez C, D El Hajj Diab, V Connord, P Clerc, E Meunier, B Pipy, B Payre, RP Tan, M Gougeon, , et al. (2014). Targeting a G-protein-coupled receptor overexpressed in endocrine tumors by magnetic nanoparticles to induce cell death. ACS Nano 8:1350-1363.
23. Barth BM, R Sharma, EI Altinoglu, TT Morgan, SS Shanmugavelandy, JM Kaiser, CO McGovern, GL Matters, JP Smith, , et al. (2010). Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano 4:1279-1287.
24. Pan W, P Xin and GA Clawson. (2008). Minimal-primer and primer-free SELEX protocols for selection of aptamers from random DNA libraries. BioTechniques 44:351-360.
25. Fino KK, GL Matters, CO McGovern, EL Gilius and JP Smith. (2012). Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. Am J Physiol Gastrointest Liver Physiol 302:G1244-G1252.
26. Barth BM, EI Altinoglu, SS Shanmugagavelandy, J Kaiser, D Crespo-Gonzalez, NA DiVittore, CO McGovern, TM Goff, NR Keasey, , et al. (2011). Targeted indocyaninegreen-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 5: 5325-5337.
27. Dufresne M, C Seva and D Fourmy. (2006). Cholecystokinin and gastrin receptors. Physiol Rev 86:805-847.
28. Magnan R, C Escrieut, V Gigoux, K De, P Clerc, F Niu, J Azema, B Masri, A Cordomi, , et al. (2013). Distinct CCK-2 receptor conformations associated with beta-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist. J Am Chem Soc 135:2560-2573.
29. Smith M, I Chen, Q Zhan, I Bae, C Chen, T KGilmer, M Kastan, P O'Connor and A Fornace. (1994). Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380.
30. Yan AC and M Levy. (2009). Aptamers and aptamer targeted delivery. RNA Biol 6:316-320.
31. Zucker M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucl Acids Res 31: 3406-3415/.
32. Miller LJ and F Gao. (2008). Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther 119:83-95.
33. Foucaud M, E Archer-Lahlou, E Marco, IG Tikhonova, B Maigret, C Escrieut, I Langer and D Fourmy. (2008). Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin. Regul Pept 145:17-23.
34. Smith JP, AP Fantaskey, G Liu and IS Zagon. (1995). Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268:R135-R141.
35. Smith JP, A Shih, Y Wu, PJ McLaughlin and IS Zagon. (1996). Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 270:R1078-R1084.
36. Xu J, IT Teng, L Zhang, S Delgado, C Champanhac, S Cansiz, C Wu, H Shan and W Tan. (2015). Molecualr recognition of human liver cancer cells using DNA aptamers generated via cell-SELEX. PLoS One 10:e125863.
37. Melacon MP, M Zhou, R Zhang, C Xiong, P Allen, X Wen, Q Huang, M Wallace, JN Myers, , et al. (2014). Selective uptake and imaging of aptamer-and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer. ACS Nano 8:4530-4538.
38. Li SD and L Huang. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharaceutics 5:496-504.
39. Ernsting MJ, M Murakami, A Roy and SD Li. (2013). Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172:782-794.
40. Salvati A, AS Pitek, MP Monopoli, FB Bombelli, DR Hristov, PM Kelly, C Aberg, E Mahon and KA Dawson. (2013). Transferrin-functinalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8:137-143.
41. Tabakovic A, M Kester and JH Adair. (2012). Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 4:96-112.
42. Jiang JX, JJ Keating, EM Jesus, RP Judy, B Madajewski, O Venegas, OT Okusanya and S Singhal. (2015). Optimization of the enhanced permeability and retention effect for near-infrared imaging of solid tumors with indocyanine green. Am J Nucl Med Mol Imaging 5:390-400.
43. Xiang D, C Zheng, SF Zhou, S Qiao, PH Tran, C Pu, Y Li, L Kong, AZ Kouzani, , et al. (2015). Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics 5:1083-1097.
44. Smith JP, TK Cooper, CO McGovern, EL Gilius, Q Zhong, JC Liao, AA Molinolo, JS Gutkind and GL Matters. (2014). Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas 43:1050-1059.